Navigation Links
Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles 'Snuffy' Myers Announces Vitamin D Clinical Trials

CHARLOTTESVILLE, Va., April 16 /PRNewswire-USNewswire/ -- The Foundation for Cancer Research and Education (FCRE) announced today that prostate cancer oncologist and survivor, Dr. Charles "Snuffy" Myers, will lecture on new treatments for prostate cancer at Westminster at Lake Ridge, VA on April 26, 2008 from 9:30 AM--12:30 PM.

"With the recent press around prostate cancer vaccines, people are very excited about new treatments," Myers says. "The good news is there are many things people can do to prevent recurrence before it starts."

Some of those treatments include:

-- Celebrex

-- Proscar/Avodart

-- Leukine

-- Calcitriol

-- Avastin

-- Mediterranean heart healthy diet

-- Vitamin D3

-- Pomegranate.

In addition, to his lecture, Dr Myers will also be announcing his new clinical trials meant to investigate one of the most promising of those treatments -- vitamin D3.

"The current research and what I see in my patients suggests that vitamin D can dramatically slow the PSA doubling times that indicate recurrent and often lethal disease," Myers says. "The trials are meant to show Vitamin D3's role in slowing or stopping the growth of prostate cancer that has recurred after surgery or radiation in a much more substantive way." Information about the trial and how to participate will be provided at the meeting.

The program, located at Westminster at Lake Ridge, 12191 Clipper Drive, Lake Ridge or Woodbridge, VA, is free of charge and includes a heart-healthy buffet breakfast for all attendees. Sponsors include FCRE, The Virginia Prostate Cancer Coalition, Us TOO, Westminster at Lake Ridge, and Potomac Hospital.

This will be the fourth time Myers has presented at Lake Ridge but the first time he publicly announces the foundation's new research efforts.

"Myers's always provides informative lectures," notes Richard Gillespie, head of the Lake Ridge Us TOO Chapter. "But we're eager to hear about the new trials Dr. Myers is working on."

For information on the event or directions please call Richard Gillespie at 703-497-0628.

About FCRE

The Foundation for Cancer Research and Education (FCRE) is dedicated to cutting edge research and clinically driven educational programs. A streamlined organization with specific research goals, FCRE's mission is to prolong patients' lives with focused research strategies. For more information or for a list of FCRE's outreach programs call 800-305-2432 or go to

SOURCE Foundation for Cancer Research and Education
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 Une ... photodynamique au Bremachlorin contre le cancer avancé. ... à combiner l,immunothérapie au traitement photodynamique au Bremachlorin ... Une nouvelle approche consistant à combiner ... cancer avancé.    Clinical Cancer ...
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, Inc. ... has completed the acquisition of Kremers Urban Pharmaceuticals ... of global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... Lannett has acquired KU from UCB for total ... adjustments, including a customary working capital adjustment, a ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. However, ... other from Bradley Beach, New Jersey, there is an easy solution to the problem. ... NuvaRings more often than necessary. As such, it affords peace of mind and eliminates ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is ... panels to choose from, the possibilities are endless. Users have full control over angle ... ProPanel: Pulse masking effects, users are sure to get heads to turn. , ProPanel: ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released a ... Mesothelioma has just posted the findings on the website. Click here to read ... of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among ...
Breaking Medicine News(10 mins):